Anti-TSG101 antibodies and their uses for treatment of viral infections

• US 7,964,708 B2
• Filed: 11/15/2007
• Issued: 06/21/2011
• Est. Priority Date: 11/15/2006
• Status: Expired due to Fees

• Current Assignee: Eli Lilly and Company
• Original Assignee: Functional Genetics Incorporated
• Inventors: Duan, Roxanne, Goldblatt, Michael, Li, Limin, Kinch, Michael
• Primary Examiner(s): LI, BAO Q
• Application Number:
  US11/940,714
• Publication Number:
  US 20080187528A1
• Time in Patent Office: 1,314 Days
• Field of Search: 424/93.1, 424/130.1, 530/300, 530/388.1
• US Class Current: 530/388.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 16/28 against receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

The present invention provides antibodies that bind to the C-terminal region of TSG101. The invention also provides methods of using the TSG101 antibodies for the treatment of viral infections, including HIV and Ebola virus infection.

Claims

1. A pharmaceutical composition for inhibiting viral infection due to human immunodeficiency virus, Ebola virus or influenza virus in a mammalian subject, comprising:

1) an effective amount of an anti-TSG101 antibody CB8, ATCC Deposit PTA-9611 or an antibody comprising the entire set of CDRs of antibody CB8, ATCC Deposit PA-9611; and

2) a pharmaceutically acceptable carrier.

3. The method of claim 1, wherein the antibody is CB8.

4. The method of claim 1, wherein said virus is a human immunodeficiency virus.

5. The method of claim 1, wherein said mammalian subject is a non-human.

6. The method of claim 1, wherein said anti-TSG101 antibody is provided to said mammalian subject by administering said antibody to said mammalian subject.

7. The method of claim 1, wherein said virus is Ebola virus.

8. The method of claim 1, wherein said virus is influenza virus.

2. A method for inhibiting viral budding in a mammalian subject, comprising providing to said subject an effective amount of an anti-TSG101 antibody CB8, ATCC Deposit PTA-9611, or an antibody comprising the entire set of complementarity determining regions (CDRs) of CB8, ATCC Deposit PTA-9611, wherein said antibody binds TSG101 present on cells of said mammalian subject which may become infected with said virus and wherein said virus is human immunodeficiency virus, ebola virus or influenza virus.